Neoleukin Therapeutics Historical PE Ratio image   This NLTX PE ratio history page last updated 11/17/2023
Neoleukin Therapeutics Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2023
11/14/2023
3.50-0.41-1.64NA
Q2 2023
8/10/2023
3.16-0.20-0.80NA
Q1 2023
5/8/2023
4.40-0.20-0.80NA
Q4 2022
3/20/2023
3.37-1.20-4.80NA
Q3 2022
11/14/2022
2.65-1.20-4.80NA
Q2 2022
8/9/2022
4.88-1.40-5.60NA
Q1 2022
5/9/2022
5.70-0.28-1.12NA
Q4 2021
3/1/2022
12.70-0.27-1.08NA
Q3 2021
11/4/2021
37.20-1.40-5.60NA
Q2 2021
8/5/2021
37.50-1.35-5.40NA
Q1 2021
5/12/2021
53.40-1.35-5.40NA
Q4 2020
3/25/2021
58.40-1.15-4.60NA
Q3 2020
11/9/2020
58.00-0.95-3.80NA
Q2 2020
8/12/2020
59.95-1.00-4.00NA
Q1 2020
5/6/2020
62.50-0.90-3.60NA
Q4 2019
3/12/2020
37.65-0.30-1.20NA
Q3 2019
11/13/2019
14.60-2.20-8.80NA
Q2 2019
7/31/2019
13.350.000.00NA
Q1 2019
5/7/2019
13.40-0.45-1.80NA
Q4 2018
3/7/2019
13.35-1.00-4.00NA
Q3 2018
11/7/2018
12.65-3.20-12.80NA
Q2 2018
8/8/2018
15.200.602.406.3
Q1 2018
5/8/2018
65.55-3.10-12.40NA
Q4 2017
3/12/2018
81.85-3.45-13.80NA
Q3 2017
11/8/2017
55.35-2.50-10.00NA
Q2 2017
8/8/2017
71.30-2.95-11.80NA
Q1 2017
5/9/2017
74.45-1.80-7.20NA
Q4 2016
3/9/2017
87.15-2.40-9.60NA
Q3 2016
11/9/2016
63.10-2.30-9.20NA
Q2 2016
8/4/2016
48.05-3.15-12.60NA
Q1 2016
5/10/2016
35.55-1.95-7.80NA
Q4 2015
3/14/2016
42.15-1.35-5.40NA
Q3 2015
11/10/2015
67.80-2.15-8.60NA
Q2 2015
8/6/2015
8.95-2.20-8.80NA
Q1 2015
5/12/2015
38.90-3.00-12.00NA
Neoleukin Therapeutics PE History Chart
PeriodPriceGAAPTTMPE
Q3 2023
11/14/2023
3.50-0.41-0.81NA
Q2 2023
8/10/2023
3.16-0.20-2.80NA
Q1 2023
5/8/2023
4.40-0.20-4.00NA
Q4 2022
3/20/2023
3.37-1.20-4.08NA
Q3 2022
11/14/2022
2.65-1.20-2.88NA
Q2 2022
8/9/2022
4.88-1.40-1.95NA
Q1 2022
5/9/2022
5.70-0.28-1.95NA
Q4 2021
3/1/2022
12.70-0.27-4.37NA
Q3 2021
11/4/2021
37.20-1.40-5.25NA
Q2 2021
8/5/2021
37.50-1.35-4.80NA
Q1 2021
5/12/2021
53.40-1.35-4.45NA
Q4 2020
3/25/2021
58.40-1.15-4.00NA
Q3 2020
11/9/2020
58.00-0.95-3.15NA
Q2 2020
8/12/2020
59.95-1.00-4.40NA
Q1 2020
5/6/2020
62.50-0.90-3.40NA
Q4 2019
3/12/2020
37.65-0.30-2.95NA
Q3 2019
11/13/2019
14.60-2.20-3.65NA
Q2 2019
7/31/2019
13.350.00-4.65NA
Q1 2019
5/7/2019
13.40-0.45-4.05NA
Q4 2018
3/7/2019
13.35-1.00-6.70NA
Q3 2018
11/7/2018
12.65-3.20-9.15NA
Q2 2018
8/8/2018
15.200.60-8.45NA
Q1 2018
5/8/2018
65.55-3.10-12.00NA
Q4 2017
3/12/2018
81.85-3.45-10.70NA
Q3 2017
11/8/2017
55.35-2.50-9.65NA
Q2 2017
8/8/2017
71.30-2.95-9.45NA
Q1 2017
5/9/2017
74.45-1.80-9.65NA
Q4 2016
3/9/2017
87.15-2.40-9.80NA
Q3 2016
11/9/2016
63.10-2.30-8.75NA
Q2 2016
8/4/2016
48.05-3.15-8.60NA
Q1 2016
5/10/2016
35.55-1.95-7.65NA
Q4 2015
3/14/2016
42.15-1.35-8.70NA
Q3 2015
11/10/2015
67.80-2.15NANA
Q2 2015
8/6/2015
8.95-2.20NANA
Q1 2015
5/12/2015
38.90-3.00NANA
Quotes delayed 20 minutes

Email EnvelopeFree NLTX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Neoleukin Therapeutics (NLTX) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

NMRA PE Ratio History
NMTC PE Ratio History
NMTR PE Ratio History
NOTV PE Ratio History
NOVN PE Ratio History
NPCE PE Ratio History
NRBO PE Ratio History
NRC PE Ratio History
NRIX PE Ratio History
NSTG PE Ratio History
How should the NLTX historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Neoleukin Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this NLTX Historical PE Ratio page.

What is the average historical PE for NLTX based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The NLTX historical PE ratio using the annualized quarterly earnings method works out to 6.3.

What is the average historical PE for NLTX based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The NLTX historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the Neoleukin Therapeutics Historical PE Ratio information for Neoleukin Therapeutics' stock. The average NLTX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 6.3. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average NLTX historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this NLTX historical PE result, against the recent PE: when this page was posted on 11/16/2023, the most recent closing price for NLTX had been 3.29, and the most recent quarterly earnings result, annualized, was 2.4. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent NLTX PE on 11/16/2023 based on annualized quarterly EPS was 1.4. Based on NLTX's history, that recent PE is low relative to the historical average, with the recent PE 77.8% lower than the historical average PE across our data set for Neoleukin Therapeutics.

For self directed investors doing their due diligence on NLTX or any other given stock, valuation analysis for NLTX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Neoleukin Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for NLTX. Thanks for visiting, and the next time you need to research NLTX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: BTCM Stock Predictions, Top Ten Hedge Funds Holding NXTD, Institutional Holders of VPN.

 

Neoleukin Therapeutics Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.